Experts explain stage IV lung cancer goals, PD‑L1-driven therapy choices, and when to intensify with chemo plus dual ...
Panelists discuss how they will explore optimizing care for patients with ALK-positive non-small cell lung cancer (ALK+ NSCLC) through treatment selection, sequencing strategies, and interpretation of ...
Evaluating the Khorana score in advanced EGFR-mutated NSCLC patients receiving first-line osimertinib. Nimotuzumab plus chemotherapy in the posterior-line treatment for lung adenocarcinoma with ...
The ongoing Italian clinical and research FPG500 program is designed to tailor matched targeted therapies (MTTs) based on "biomarkers predictive of response identified by comprehensive genome profiling ...
Please provide your email address to receive an email when new articles are posted on . Most patients with nonsquamous NSCLC treated at academically-affiliated community clinics received ...
Caris Life Sciences aims to standardize MET immunohistochemistry testing for non-squamous non-small cell lung cancer to enhance molecular insights and treatment personalization. MET protein expression ...
The FDA approved the Oncomine Dx Express Test for rapid identification of NSCLC patients eligible for Zegfrovy treatment. The test provides results in 24 hours, aiding timely therapeutic decisions and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results